MedCity News
NOVEMBER 6, 2022
Instead of EHR companies trying to build solutions in-house, collaborating with a patient engagement technology provider is the simplest and most cost-effective way for them to deliver the communication link demanded by today’s healthcare consumer.
pharmaphorum
NOVEMBER 6, 2022
Eli Lilly plans for a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients for its biologic medicines, including its new Alzheimer’s candidate donanemab, has been blocked by a planning objection. Lilly had already secured planning approval from Limerick City and County Council for the plant at the Raheen Business Park.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
NOVEMBER 6, 2022
Northeast Business Group on Health’s new survey tool is called Well Gauge. After employers answer a series of questions, the tool will provide a score and a list of recommendations to improve mental wellness at their company.
Cesare Ferrari
NOVEMBER 6, 2022
This article was originally published on Meddeviceonline on September 19, 2022. Every medtech company aims to build a successful product and have a seamless launch. But for this to happen, you must first identify early adopters of your new medical product. Let’s explore this concept in some detail. Who Are Early Adopters? The media often define early adopters as a customer segment of young, well-off, and tolerant to risk individuals keen to try new technologies.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
NOVEMBER 6, 2022
On Thursday, Forrester released a report predicting major trends that would shape healthcare in 2023. Healthcare stakeholders should prepare for key changes, such as care becoming even more inaccessible for rural patients and additional retail entrants into the clinic space.
Pharmacy Times
NOVEMBER 6, 2022
Controlling blood pressure may be the most important type of treatment for vasculitis and lupus patients, said a professor of renal medicine at ASN Kidney Week in Orlando, Florida.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmacy Times
NOVEMBER 6, 2022
Next-generation research shows that targeting specific Kir channels, which regulate salt reabsorption in the kidneys, could improve diuretic function in kidney patients.
PharmExec
NOVEMBER 6, 2022
Here are three mindsets for pharma companies to adopt now to reap the rewards of early action in the metaverse.
Pharmacy Times
NOVEMBER 6, 2022
Active patient care with chronic kidney disease may provide enormous benefits for patients, the economy, and society.
Map My Customers
NOVEMBER 6, 2022
Data visualization, location intelligence , and automation are essential for field sales teams to be as successful as possible. In today’s sales environment using the right software can give both reps and sales leaders a deeper understanding of their territories, help manage them more effectively, and supercharge reps’ productivity. You know you want to empower your reps with everything they need to be successful, but you’re probably wondering which specific software is best
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmacy Times
NOVEMBER 6, 2022
Beth Macy, author of New York Times-bestselling book Dopesick and executive producer and writer on the Hulu series “Dopesick,” explains how FDA-approved drugs that treat opioid use disorder still aren’t getting into the hands of patients who need it most.
pharmaphorum
NOVEMBER 6, 2022
The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were mAbs and this trend is forecasted to remain the same over the next five years. Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline.
Pharmacy Times
NOVEMBER 6, 2022
Daprodustat is suggested to improve anemia and quality-of-life in patients with chronic kidney disease.
pharmaphorum
NOVEMBER 6, 2022
AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody-based drug has been cleared by the European Commission with a broad label, covering both full-term and pre-term babies and those with a range of health conditions that could make the vulnerable to RSV, said the two pharma groups in a statement.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmacy Times
NOVEMBER 6, 2022
American Society of Consultant Pharmacists executive director and CEO explained how staffing struggles in long-term care facilities can be an opportunity for pharmacists to expand the ways they provide support beyond immunizations alone.
Pharmacy Times
NOVEMBER 6, 2022
Experts said the results will likely not alter practice and clinicians will likely continue to use torsemide.
Expert insights. Personalized for you.
119 
Let's personalize your content